TAJUDEEN KOLAWOLE: Open Payments
NPI 1861091191 · CHESTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,538 in 132 payments from 10 companies in 2025. Trend: 2023 $261 · 2024 $628 · 2025 $2,538
Food & beverage: $2,538
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 40 | $654 |
| Neurocrine BioSciences, Inc. | 16 | $464 |
| Alkermes, Inc. | 29 | $363 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $238 |
| E.R. Squibb & Sons, L.L.C. | 8 | $226 |
| Vanda Pharmaceuticals Inc. | 6 | $188 |
| ABBVIE INC. | 11 | $153 |
| Janssen Pharmaceuticals, Inc | 4 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Lundbeck LLC | 2 | $47 |
Products named: INGREZZA, UZEDY, ARISTADA, CAPLYTA, AUSTEDO XR, COBENFY, FANAPT, VRAYLAR.
Industry payments across PA — which companies pay providers there.
